Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

Novo Nordisk’s Diabetes Drug Becomes Second Ever To Show Cardiovascular Benefit

XTALKS VITALS NEWS

Cardiovascular

The findings are a major boost for the diabetes drug, which is the second ever drug of its kind to show a cardiovascular benefit.

Share this!

June 16, 2016 | by Sarah Massey, M.Sc.

Tweet: Novo Nordisk’s #diabetes drug reduced risk of cardiovascular episodes http://ctt.ec/6oS0b+ A recent clinical trial found that Novo Nordisk’s diabetes medication Victoza – an injectable GLP-1 receptor agonist – reduced the risk of cardiovascular episodes by 13 percent. The findings are a major boost for the diabetes drug, which is the second ever drug of its kind to show a cardiovascular benefit.

In 2015, Eli Lilly and Boehringer Ingelheim reported that their diabetes drug, Jardiance, reduced the risk of cardiovascular events in patients with type 2 diabetes by 14 percent, along with a 38 percent reduction in cardiovascular deaths. Ever since, other diabetes drug companies have been conducting their own clinical trials to try to establish similar cardiovascular benefits.



According to a Novo Nordisk press release, Victoza reduced heart disease-related deaths by 22 percent over the placebo. Despite the company’s unexpected 5 percent dip in stock price following the announcement, Novo Nordisk believes the positive results could boost sales of Victoza over its $2.7 billion in revenue in 2015.

In addition to Eli Lilly, Boehringer Ingelheim and Novo Nordisk, other pharmaceutical giants are quickly establishing cardiovascular clinical trials. Merck and Pfizer have announced that they will be enrolling more patients in a clinical trial studying the cardiovascular outcomes of their experimental drug, ertugliflozin.

The Novo Nordisk clinical trial of Victoza – named LEADER – involved 9,340 patients with type 2 diabetes who were considered to be at a high risk of developing cardiovascular disease. The composite endpoint for the trial included non-fatal myocardial infarction, stroke and cardiovascular-related death.

“We are very excited by the LEADER trial results that demonstrate a significant reduction in major cardiovascular events among type 2 diabetes patients treated with Victoza, including all-cause death,” said Mads Krogsgaard Thomsen, executive vice president and chief science officer of Novo Nordisk. “For us, this marks the beginning of a new era where our R&D focus will go beyond glucose control.”


Keywords: Diabetes, Cardiovascular, Clinical Trial


| NEXT ARTICLE | MORE NEWS | BLOGS | VIDEOS | POLLS & QUIZZES | WEBINARS |

Share this with your colleagues!

MORE NEWS
Lavazza Acquires Controlling Stake in Canada’s Kicking Horse Coffee

May 26, 2017 - Italian coffee company Lavazza, has secured an 80 percent equity stake in Canadian organic and fair-trade coffee company Kicking Horse Coffee, in a deal worth CAD$215 million.

Featured In: Food News


FDA First: Keytruda Approved for Cancer Treatment Based on Biomarker Alone

May 25, 2017 - For the first time, the FDA has approved a cancer treatment for solid tumors based on the presence of a biomarker, as opposed to specifying a tissue of origin.

Featured In: Biotech News


One Year of Medically Assisted Dying in Canada

May 25, 2017 - In June of 2016, the federal government of Canada passed legislation to legalize medically assisted dying.

Featured In: Life Science News


LEAVE A COMMENT
 
  
THE XTALKS VITALS INDUSTRY BLOG

Top 5 Most Impactful Tweets in Life Sciences During the Last Week

REGISTER FOR THESE WEBINARS

EU IVD Regulation: Top Five Changes for Medical Device Manufacturers to Consider


Thermal Processing Systems for the Food Industry: A Guide to Selecting Thermal Equipment and Technology


Rare Disease & Orphan Drug Development: Cost-Efficient Trial Design to Minimize Cash Burn


eTMF Workflows: Active eTMF to Improve the Quality of Clinical Trials


Copyright © 2016-2017 Honeycomb Worldwide Inc.